Share on StockTwits

Investment analysts at Stifel Nicolaus raised their price objective on shares of Edwards Lifesciences Corp (NYSE:EW) from $90.00 to $100.00 in a note issued to investors on Thursday. Stifel Nicolaus’ price objective would suggest a potential upside of 8.73% from the company’s current price.

In other Edwards Lifesciences Corp news, VP Patrick B. Verguet sold 5,000 shares of Edwards Lifesciences Corp stock on the open market in a transaction dated Friday, August 1st. The shares were sold at an average price of $92.00, for a total value of $460,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% during mid-day trading on Thursday, hitting $91.97. The stock had a trading volume of 1,899,876 shares. Edwards Lifesciences Corp has a 52 week low of $60.62 and a 52 week high of $94.50. The stock has a 50-day moving average of $85.98 and a 200-day moving average of $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.

Edwards Lifesciences Corp (NYSE:EW) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.88 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter last year, the company posted $0.82 earnings per share. Edwards Lifesciences Corp’s revenue was up 11.2% compared to the same quarter last year. On average, analysts predict that Edwards Lifesciences Corp will post $3.28 earnings per share for the current fiscal year.

A number of other firms have also recently commented on EW. Analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday. Separately, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday. Finally, analysts at BMO Capital Markets raised their price target on shares of Edwards Lifesciences Corp from $84.00 to $89.00 in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $90.00.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.